Summary. Glucagon-like peptide I (GLP-1) (7-36 amide) is a physiological incretin hormone that is released after nutrient intake from the lower gut and stimulates insulin secretion at elevated plasma glucose concentrations. Previous work has shown that even in Type 2 (non-insulindependent) diabetic patients GLP-1 (7-36 amide) retains much of its insulinotropic action. However, it is not known whether the magnitude of this response is sufficient to normalize plasma glucose in Type 2 diabetic patients with poor metabolic control. Therefore, in 10 Type 2 diabetic patients with unsatisfactory metabolic control (HbA~ 11.6 +_ 1.7 %) on diet and sulphonylurea therapy (in some patients supplemented by metformin or acarbose), 1.2 pmol x kg-I x min-t GLP -1 (7-36 amide) or placebo was infused intravenously in the fasting state (plasma glucose 13.1 _+ 0.6 mmol/1). In all patients, insulin (by 17.4 + 4.7 nmol • ~xmin; p=0.0157) and C-peptide (by 228.0+39.1 nmol x i ~ • min; p = 0.0019) increased significantly over basal levels, glucagon was reduced (by -1418 _+ 308 pmol x 1-1x min) and plasma glucose reached normal fasting concentrations (4.9+0.3mmol/1) within 4h of GLP-1 (7-36 amide) administration, but not with placebo. When normal fasting plasma glucose concentrations were reached insulin returned towards basal levels and plasma glucose concentrations remained stable despite the ongoing infusion of GLP-1 (7-36 amide). Therefore, exogenous GLP-1 (7-36 amide) is an effective means of normalizing fasting plasma glucose concentrations in poorly-controlled Type 2 diabetic patients. The glucose-dependence of insulinotropic actions of GLP-1 (7-36 amide) appears to be retained in such patients.
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Glucagon-like peptide I (7-36 amide) is an insulinotropic hormone secreted from enteroglucagon-producing cells in the lower gut, i.e. the distal jejunum, ileum and colon/rectum [1] . Since after meals plasma concentrations increase and reach the concentration range necessary to stimulate insulin secretion, GLP-1 (7-36 amide), together with gastric inhibitory polypeptide (GIP) from the upper gut, act as physiological incretin hormones [2, 3] . In pharmacological concentrations, exogenous GLP-1 (7-36 amide or 7-37) raised insulin and lowered glucagon concentrations also in Type 2 (non-insulin-dependent) diabetic patients [4, 5] . It also reduced meal-related insulin requirements in both Type 1 (insulin-dependent) and Type 2 diabetic patients [6] . However, after a mixed meal, not only influences on insulin and glucagon secretion, but also other effects, such as an inhibition of gastric emptying may have contributed to the "anti-diabetogenic effect" [7] . Therefore, the aim of the present study was to characterize the endocrine pancreatic and glucose response to a pharmacological dose of exogenous GLP-1 (7-36 amide) in fasting Type 2 diabetic patients. The subjects were selected to represent a group of Type 2 diabetic patients which could not be satisfactorily controlled by oral antidiabetic drugs. Since the expected insulinotropic response involves the potential risk of hypoglycaemic reactions, it was of special interest to evaluate the glucose-dependence of the insulin response to GLP-1 (7-36 amide) in these patients, i.e. to see whether the insulin response declines again when normal fasting glucose concentrations are approached.
Subjects, materials and methods

Study protocol
The study protocol was approved by the ethics committee of the medical faculty of the Georg-August-University, G6ttingen prior to the study. Written informed consent was obtained from all participants. 
Patients
Blood specimens
Ten Type 2 diabetic patients were studied (Table 1) . They were all being treated with diet and sulphonylurea compounds, and some were also receiving metformin or acarbose treatment. Multiple fasting plasma glucose concentrations (from hospital charts) were 13.1 + 2.0 mmolfl (236 + 36 mg/dl), postprandial glucose concentrations were 15.1 + 2.7 mmol/1 (272 + 49 mg/dl). Because of unsatisfactory metabolic control, eight of these ten patients were assigned to insulin treatment immediately after the study. The patients were studied on two occasions. All anti-diabetic medication was continued until the morning before the studies. A regular meal and drug schedule was allowed for one day between the experiments with GLP-1 (7-36 amide) and placebo. On the study days, all medication was withheld until the end of the experiments.
Peptides
Synthetic GLP-1 (7-36 amide) was purchased from Saxon Biochemicals GmbH, Hannover, FRG. The same lot number was used as in previous studies (GLP-1 (7-36 amide): PGAS 242, Lot ZE 865, net peptide content 79.3 % ) [3, 4] . The peptide was dissolved, filtered through 0.2 gm nitrocellulose filters (Millipore, Bedford, Mass., USA) and stored frozen at -30~ as previously described. Net peptide content rather than gross weight was used for dose calculations. HPLC profiles (provided by the manufacturer) showed that the preparation was more than 99 % pure (single peak coeluting with appropriate standards). Samples were analysed for bacterial growth (standard culture techniques) and for pyrogens (Limulus amebocyte lysate endo-LAL; Chromogenix AB, MOlndal, Sweden). No bacterial contamination was detected. Endotoxin concentrations in the GLP-1 (7-36 amide) stem solutions were always less than 0.03 EU/ml.
Experimental procedures
The experiments were performed in randomized ,order. The tests were performed in the morning after an overnight fast. Two forearm veins were punctured with a teflon cannula (Moskito 123, 18 gauge; Vygon, Aachen, FRG), which was kept patent using 0.9 % NaC1 (for blood sampling and for GLP-1 (7-36 amide)/placebo administration).
After drawing basal blood specimens at 0 rain, an intravenous infusion of GLP-1 (7-36 amide) or placebo (0.9 % NaC1 containing 1% human serum albumin; Merieux, Norderstedt, FRG) was started at an infusion rate of 1.2 pmol/kg per min and continued for 240 min. Blood was drawn at 30-min intervals and plasma glucose was determined immediately.
Blood was drawn into heparinized tubes (immunoreactive (IR) insulin and C-peptide measurements). A sample was stored in NaF (Microvette CB 300; Sarstedt, Ntimbrecht, FRG) for the measurement of glucose. For glucagon and GLP-1 (7-36 amide) measurements blood was drawn into tubes containing EDTA and aprotinin (Trasylol; 20000kallikrein inhibition units/ml, 200 gl per 10ml blood; Bayer AG, Leverkusen, FRG). After centrifugation, plasma for hormone analyses was kept frozen at -30~
Laboratory determinations
Glucose was measured using a glucose oxidase method with a Glucose Analyser 2 (Beckman Instruments, Munich, FRG). Plasma IRinsulin and C-peptide were determined using commercial radioimmunoassay kits (Insulin RIA 100; Pharmacia, Freiburg, FRG; RIAmat C-peptide II, Byk-Sangtec Diagnostika, Dietzenbach, FRG), with human insulin and C-peptide as standard.
IR-GLP-1 was determined in ethanol-extracted plasma as previously described [8] , using antiserum 2135 (final dilution 1:150000) and synthetic GLP-1 (7-36 amide) for tracer preparation and as standard. Recovery of GLP-1 (7-36 amide) standards after alcohol extraction was 75 + 8 %. The experimental detection limit (2 SD over samples not containing GLP-1 (7-36 amide)) was less than 5 pmol/1. Antiserum 2135 binds, with approximately equal affinity, to all proglucagon-derived peptides containing the GLP-1 (7-36 amide) sequence, regardless of amino-or carboxy-terminal extensions. Pancreatic glucagon was assayed in ethanol-extracted plasma using antibody 4305 [9] .
Non-esterified fatty acids were quantitated enzymatically with acyl-CoA oxidase from Candida tropicalis using a Hitachi 705 autoanalyser. Reagents were from Wako Chemicals (Neuss, FRG). Each patient's set of plasma samples was assayed at the same time to avoid errors due to inter-assay variation.
Statistical analysis
Results are reported as mean + SEM. Integration was carried out according to the trapezoidal rule. Significances of differences were tested using repeated measurement analysis of variance (RM-ANOVA; NCSS Version 5.01, Kaysville, Utah, USA). If a significant interaction of treatment and time was documented (p < 0.05), values at single time points were compared by Student's t-test (paired analyses). P-values were corrected for the number of comparisons made according to Bonferroni-Holm. A corrected two-sided p-value less than 0.05 was taken to indicate significant differences. ,7.5 :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 300 
Results
The mean fasting plasma glucose concentrations before the exogenous administration of GLP-1 (7-36 amide) was 12.7 + 0.6 mmoV1. GLP-1 (7-36 amide) lowered plasma glucose in all 10 Type 2 diabetic patients (Fig.l) . After 240 min, "normal" basal plasma concentrations were reached (4.9 + 0.3 mmol/1), whereas with placebo, only a slight reduction in plasma glucose concentrations was noted ( The steady-state concentration of GLP-1 (7-36 amide) was 123 + 10 pmol/1 with exogenous GLP-1 (7-36 amide). With placebo, the values remained in the basal range (8 + 1 pmol/1; Fig. 2, upper panel) .
Pancreatic glucagon was significantly lowered with exogenous GLP-1 (7-36 amide) by -1418 +308 pmol • 1-1• min; Fig.2 , middle panel) despite a considerable fall in plasma glucose (Fig. 1, upper panel) . When plasma glucose approached normal fasting levels, glucagon returned to baseline values.
During the exogenous administration of GLP-1 (%36 amide), plasma non-esterified fatty acids significantly decreased (by -26.3+3.1mmolxl -Ixmin) during the period characterized by elevated insulin and reduced glucagon concentrations (Fig. 2 , lower panel;p = 0.028).
Discussion
The results of the present study indicate that the preserved incretin activity of GLP-1 (7-36 amide) may be utilized to normalize fasting plasma glucose concentrations in Type 2 diabetic patients. This is an extension of previous observations where, in mildly Type 2 diabetic patients, GLP-1 (7-36 amide) as aninsulinotropic agent was found to be almost equally as effective as in age-and weight-matched normal subjects [4] . Therefore, the insulinotropic effect of GLP-1 (7-36 amide) is of sufficient magnitude to reduce elevated plasma glucose concentrations into the normal fasting range even in patients who no longer respond well to oral anti-diabetic drugs. The concentrations of GLP-1 (7-36 amide) reached with an infusion rate of 1.2 pmol x kg-1 x min-1 were approximately two-to three-fold higher than peak values measured after oral glucose when using the same radioimmunoassay [3, 4] . Therefore, the actions of GLP-1 (7-36 amide) observed in the present study are pharmacological effects, although the difference in circulating concentrations to those encountered under physiological conditions was not great.
The amount of insulin secreted in response to GLP-1 (7-36 amide) can be estimated to be approximately 11.9 + 2.3 U [10] . The glucagon-lowering effect of GLP-1 (7-36 amide) [4, [11] [12] [13] may contribute to the normalization of plasma glucose concentrations. However, when considering the different glucose concentration curves in the GLP-1 (7-36 amide) and placebo experiments, the influence of GLP-1 (7-36 amide) on pancreatic alpha cell secretion cannot be judged without accounting for the influence of glucose itself. The elevation in insulin concentrations may have contributed to the reduction in pancreatic glucagon. However, in some patients insulin and C-peptide increased very little. Nevertheless, glucagon concentrations were lowered and glucose concentrations were normalized (details not shown). This indicates that alpha-cell inhibition contributes to the effect on plasma glucose concentrations. Additional experiments will have to weigh the relative contributions of increased beta-cell and reduced alpha-cell secretion.
In agreement with the strict glucose-dependence of insulinotropic actions of GLP-1 (7-36 amide) reported in normal subjects [2, 3, 12] , when the Type 2 diabetic patients were hyperglycaemic, insulin and C-peptide concentrations were stimulated, with a return towards basal levels when glucose concentrations approached normal fasting levels. This shows that even in poorly-controlled diabetic patients, whose plasma glucose concentrations have not been normal over a prolonged period, a similar glucose threshold exists for the insulinotropic action of GLP-1 (7-36 amide) as seen in normal subjects. This should limit the risk of hypoglycaemic responses when GLP-1 (%36 amide) or similarly acting analogues are used as therapeutic agents.
After meals, other actions of GLP-1 (7-36 amide) may help to reduce the postprandial increment in plasma glucose. GLP-1 (7-36 amide) slows the velocity of gastric emptying and thereby reduces the availability of nutrients for absorption [7] . In addition, the rise in glucose and glucagon concentrations and in meal-related insulin requirements are decreased after a test meal in Type 1 and Type 2 diabetic patients [6] .
In conclusion, in the fasting state, exogenous GLP-1 (7-36 amide) stimulates insulin and reduces glucagon secretion to a degree that leads to a normalization of plasma glucose concentrations even in poorly-controlled Type 2 M. A. Nauck et al.: GLP-1 (7-36 amide) in Type 2 diabetes diabetic patients with secondary failure after sulphonylurea treatment. Furthermore, the strict glucose-dependence of insulinotropic effects limits the amount of insulin secreted when high doses of GLP-1 (7-36 amide) are administered at near-normal fasting plasma glucose concentrations.
